SCHEMBL14280507

SCHEMBL14280507

Cc1cc(C(C)C)cc2c1NC(=O)NC2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA4 P22748 1/20 0.34
CA7 P43166 1/20 0.34
CA9 Q16790 1/20 0.34
ADRA2A P08913 1/20 0.34
ADRA2B P18089 1/20 0.34
ADRA2C P18825 1/20 0.34
ADRA1D P25100 1/20 0.34
HTR1D P28221 1/20 0.34
HTR1B P28222 1/20 0.34
ADRA1A P35348 1/20 0.34
ADRA1B P35368 1/20 0.34
HTR2A P28223 2/20 0.33
HTR2C P28335 2/20 0.33
HTR2B P41595 2/20 0.33
MB P02144 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13052359 0.77 GRIA1 (0.41) ADRA2AADRA2BADRA2CADRA1DHTR1D
SCHEMBL13052361 0.75 KIF11 (0.41) CA9HTR2AHTR2CHTR2BCRBN
SCHEMBL13052357 0.73 ADRA2A (0.33) ADRA2AADRA2BADRA2CADRA1DHTR1D
SCHEMBL13052362 0.73 BRD4 (0.39) ADRA2AADRA2BADRA2CADRA1DHTR1D
SCHEMBL14280506 0.73 KCNH2 (0.33) ADRA2AADRA2BADRA2CADRA1DHTR1D
SCHEMBL15586617 0.72 PDE3B (0.58) PDE3BPDE3AMBCRBNMAPK1
SCHEMBL20315032 0.70 MB (0.45) PDE3BPDE3AMBCRBN
SCHEMBL14330930 0.69 ADRA2A (0.41) ADRA2AADRA2BADRA2CADRA1DHTR1D
SCHEMBL8952258 0.69 CA12 (0.45) PDE3BPDE3ACA12CA1CA2
SCHEMBL16369413 0.69 PDE3B (0.46) PDE3BPDE3AMBCRBNMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7314883-B2 Anti-migraine treatments BRISTOL-MYERS SQUIBB COMPANY (US) 2008-01-01 US disclosed
US-20070232600-A1 ANTI-MIGRAINE TREATMENTS BRISTOL-MYERS SQUIBB COMPANY 2007-10-04 US disclosed
US-7220862-B2 Calcitonin gene related peptide receptor antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2007-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232600-A1 ANTI-MIGRAINE TREATMENTS BDKRB2, PTGIR, CALCRL PDE3B 137/4885PDE3A 195/4885CA12 1785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.